As confidence returns to job seekers, high levels of staff movement could impact on organizations' growth.
As increasing numbers of pharmaceutical companies expand into Singapore, and businesses experience high levels of staff movement as a result of heightened confidence amongst jobseekers, future growth could be impacted by a marked skills shortage. That’s according to the latest Global Sentiment Survey from Berkley Group, which analyses employment and market perceptions internationally.
People crisis looms for Pharma companies
Recent reportsfrom the Ministry of Trade reveal that the Singapore economy grew 5.4% in Q1 2014 which has, in turn, led to increased investment in the region and heightened confidence amongst jobseekers and employers alike. Despite this, however, Berkley’s research reveals that future growth may be halted by a lack of available talent. The report revealed that 80% of the current workforce intends to move jobs in the next year, with 60% planning to do so within six months. This is in keeping with recent research from Sylvia Vorhauser-Smith, Senior Vice President of Research at PageUp People, which reveals that regular job hopping is prevalent in the country’s workforce.
Robust attraction and retention strategy a must for employers
This high level of predicted movement amongst the workforce is likely to exacerbate the already present concerns surrounding talent retention and attraction in Singapore. This, coupled with increasing pressure mounted on employers to hire locals before expats, means that staffing strategies need to be far more succinct to help organisations attract and retain those professionals with the requisite skill sets to prevent a slowdown in growth. This is a sentiment mirrored in Berkley’s research which reveals that, whilst 90% of those surveyed expect a pay rise in the coming year, very few reported financial incentives as a contributing factor in moving jobs (30%). In comparison, 57% acknowledged that career progression would be the biggest driver. These results suggest there is currently a significant disconnect between staff preferences and workplace incentives.
Wendy Cheong, Practice Director at Berkley Group, comments:
“The Singapore economy is currently experiencing a period of intense change as plans for economic development and growth remains a high priority for the government. However, in order for businesses to remain competitive, it’s vital that they have the right talent on board, an objective that has long been a challenge with high levels of staff turnover and a heavy reliance on expats in the country. As recruitment activity looks set to increase, there will need to be a change in the mindset of employers to ensure they are providing the right opportunities to attract and retain staff to prevent marked skills shortages. As financial incentives continue to drop off the radar of the workforce, perhaps career development opportunities need to be considered as part of the talent attraction strategy.”
To see the full report visit http://www.berkley.com.sg/research-download
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.